FORA vs. LFVN, TPST, HOOK, JATT, PSNL, AFMD, JAGX, CRVS, LPTX, and TKNO
Should you be buying Forian stock or one of its competitors? The main competitors of Forian include LifeVantage (LFVN), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), JATT Acquisition (JATT), Personalis (PSNL), Affimed (AFMD), Jaguar Health (JAGX), Corvus Pharmaceuticals (CRVS), Leap Therapeutics (LPTX), and Alpha Teknova (TKNO). These companies are all part of the "medical" sector.
LifeVantage (NASDAQ:LFVN) and Forian (NASDAQ:FORA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.
In the previous week, Forian had 1 more articles in the media than LifeVantage. MarketBeat recorded 4 mentions for Forian and 3 mentions for LifeVantage. Forian's average media sentiment score of 0.75 beat LifeVantage's score of 0.72 indicating that LifeVantage is being referred to more favorably in the media.
LifeVantage has a net margin of 1.75% compared to LifeVantage's net margin of 0.00%. Forian's return on equity of 27.02% beat LifeVantage's return on equity.
Forian has lower revenue, but higher earnings than LifeVantage. Forian is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 19.3% of Forian shares are owned by institutional investors. 6.8% of LifeVantage shares are owned by insiders. Comparatively, 31.3% of Forian shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
LifeVantage received 212 more outperform votes than Forian when rated by MarketBeat users. However, 90.00% of users gave Forian an outperform vote while only 77.82% of users gave LifeVantage an outperform vote.
Forian has a consensus target price of $7.67, indicating a potential upside of 192.62%. Given LifeVantage's higher possible upside, analysts clearly believe Forian is more favorable than LifeVantage.
LifeVantage has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Forian has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
Summary
Forian beats LifeVantage on 9 of the 17 factors compared between the two stocks.
Get Forian News Delivered to You Automatically
Sign up to receive the latest news and ratings for FORA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FORA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
